AR064212A1 - Uso de profarmacos de analogos de gaba para tratar enfermedades - Google Patents
Uso de profarmacos de analogos de gaba para tratar enfermedadesInfo
- Publication number
- AR064212A1 AR064212A1 ARP070105514A ARP070105514A AR064212A1 AR 064212 A1 AR064212 A1 AR 064212A1 AR P070105514 A ARP070105514 A AR P070105514A AR P070105514 A ARP070105514 A AR P070105514A AR 064212 A1 AR064212 A1 AR 064212A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- cycloheteroalkyl
- cycloalkyl
- heteroalkyl
- arylalkyl
- Prior art date
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 3
- 206010011224 Cough Diseases 0.000 abstract 3
- 208000001640 Fibromyalgia Diseases 0.000 abstract 3
- 208000019695 Migraine disease Diseases 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- 206010041250 Social phobia Diseases 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 208000006673 asthma Diseases 0.000 abstract 3
- 206010027599 migraine Diseases 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen métodos para usar profármacos de análogos de GABA y sus composiciones farmacéuticas para tratar migrana, fibromialgia, esclerosis lateral amiotrofica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva cronica, y composiciones farmacéuticas de profármacos de análogos de GABA de utilidad para tratar migrana, fibromialgia, esclerosis lateral amiotrofica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva cronica. Reivindicacion 1: Un método para tratar una enfermedad elegida de migrana, fibromialgia, esclerosis lateral amiotrofica, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva cronica en un paciente, que comprende administrar a un paciente que necesite dicho tratamiento una cantidad terapéuticamente efectiva de al menos un compuesto elegido de la formula (1), la formula (2), la formula (3), la formula (4), una sal farmacéuticamente aceptable de cualquiera de los anteriores, un solvato farmacéuticamente aceptable de cualquiera de los anteriores, y un N oxido farmacéuticamente aceptable de cualquiera de los anteriores, en donde: R1 es elegido de hidrogeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, y heteroarilalquilo sustituido; R2 y R3 son elegidos independientemente de hidrogeno, alquilo, alquilo sustituido, alcoxicarbonilo, alcoxicarbonilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, carbamoilo, sustituido carbamoílo, cicloalquilo, cicloalquilo sustituido, heteroalquilo, heteroalquilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, y heteroarilalquilo sustituido, o R2 y R3 junto con el átomo de carbono al que están unidos forman un anillo elegido de anillo cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, y cicloheteroalquilo sustituido; y R4 es elegido de acilo, acilo sustituido, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, y heteroarilalquilo sustituido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87356106P | 2006-12-08 | 2006-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064212A1 true AR064212A1 (es) | 2009-03-18 |
Family
ID=39186816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105514A AR064212A1 (es) | 2006-12-08 | 2007-12-10 | Uso de profarmacos de analogos de gaba para tratar enfermedades |
Country Status (13)
Country | Link |
---|---|
US (2) | US20080161393A1 (es) |
EP (1) | EP2101752A1 (es) |
JP (1) | JP2010512314A (es) |
CN (1) | CN101652133A (es) |
AR (1) | AR064212A1 (es) |
AU (1) | AU2007332904A1 (es) |
BR (1) | BRPI0720252A2 (es) |
CA (1) | CA2672044A1 (es) |
EA (1) | EA200970487A1 (es) |
MX (1) | MX2009006080A (es) |
PE (1) | PE20081389A1 (es) |
TW (1) | TW200845959A (es) |
WO (1) | WO2008073257A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
EP1670451A4 (en) * | 2003-09-11 | 2009-10-21 | Xenoport Inc | TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS |
KR101096480B1 (ko) * | 2003-10-14 | 2011-12-20 | 제노포트 인코포레이티드 | 감마-아미노부티르산 유사체의 결정질 형태 |
BRPI0517227B8 (pt) | 2004-11-04 | 2021-05-25 | Xenoport Inc | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
ATE511392T1 (de) * | 2007-01-11 | 2011-06-15 | Xenoport Inc | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit |
EP2250148B1 (en) * | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
CA2706575C (en) * | 2008-01-25 | 2015-07-14 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
WO2010017498A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing n-hydroxysuccinimidyl carbonates |
WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
AU2009302241B2 (en) * | 2008-10-08 | 2015-10-29 | Xgene Pharmaceutical Inc. | GABA conjugates and methods of use thereof |
NZ594648A (en) * | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
CA2823974A1 (en) * | 2010-01-08 | 2011-07-14 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of migraine headaches |
WO2012083128A2 (en) * | 2010-12-16 | 2012-06-21 | The Mclean Hospital Corporation | Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death |
CA2885148A1 (en) * | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
WO2014134005A2 (en) | 2013-02-26 | 2014-09-04 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
WO2016187595A2 (en) * | 2015-05-20 | 2016-11-24 | Lupin Atlantis Holdings Sa | Oral pharmaceutical composition of methylergonovine |
CN107271599A (zh) * | 2016-04-08 | 2017-10-20 | 上海市刑事科学技术研究院 | 一种人唾液中地西泮及其代谢物的在线spe lc-ms/ms分析方法 |
US11458129B2 (en) * | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
WO2019219000A1 (en) * | 2018-05-14 | 2019-11-21 | Xgene Pharmaceutical Inc. | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
DE112019007341B4 (de) * | 2019-06-20 | 2024-06-13 | Hitachi High-Tech Corporation | Substanzanalysator und substanzanalyseverfahren |
RU2709527C1 (ru) * | 2019-07-29 | 2019-12-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение пептида Met-Glu-His-Phe-Pro-Gly-Pro (семакса) для коррекции дисбиоза при хроническом иммобилизационном стрессе |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996431A (en) * | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
US3402240A (en) * | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
US3139383A (en) * | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
US3962414A (en) * | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
US3992518A (en) * | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4079038A (en) * | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4066747A (en) * | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
US4070347A (en) * | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
US4721613A (en) * | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
EP0130119B1 (en) * | 1983-06-23 | 1988-11-09 | Merck & Co. Inc. | (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives |
US4820523A (en) * | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
DE3928183A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5151448A (en) * | 1991-07-12 | 1992-09-29 | Crenshaw Roger T | Method for treating premature ejaculation |
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5276042A (en) * | 1993-04-16 | 1994-01-04 | Crenshaw Roger T | Treatment of premature ejaculation |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
US5684018A (en) * | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
DE69709070T2 (de) * | 1996-03-14 | 2002-06-20 | Warner Lambert Co | Verbrückte zyklische aminosäuren als pharmazeutische mittel |
IL125544A (en) * | 1996-03-14 | 2002-03-10 | Warner Lambert Co | Transformed cyclic amino acids and pharmaceutical preparations containing them |
US5672612A (en) * | 1996-09-09 | 1997-09-30 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
US6375987B1 (en) * | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
US6329429B1 (en) * | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
WO1999008670A1 (en) * | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
FR2779651B1 (fr) * | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
US6171615B1 (en) * | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
NZ509231A (en) * | 1998-07-09 | 2003-08-29 | Warner Lambert Co | Use of GABA analogs to treat insomnia |
US6680343B1 (en) * | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
US6490454B1 (en) * | 1998-08-07 | 2002-12-03 | Telefonaktiebolaget Lm Ericsson (Publ) | Downlink observed time difference measurements |
EP1169060B1 (en) * | 1999-04-09 | 2005-08-31 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
GB2365425A (en) * | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
US20020098999A1 (en) * | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
WO2002028881A1 (en) * | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
WO2002032376A2 (en) * | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US20040002543A1 (en) * | 2001-02-16 | 2004-01-01 | Leslie Magnus | Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1404324B2 (en) * | 2001-06-11 | 2011-04-06 | XenoPort, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
US7045549B2 (en) * | 2001-11-08 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Jr. University | Treatment of symptoms associated with irritable bowel syndrome |
MXPA04004368A (es) * | 2001-11-08 | 2004-08-11 | Sepracor Inc | Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. |
PL371944A1 (en) * | 2002-01-31 | 2005-07-11 | Warner-Lambert Company Llc | Alpha 2 delta ligands to treat tinnitus |
WO2003080588A1 (en) * | 2002-03-20 | 2003-10-02 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
US7060727B2 (en) * | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
AU2003283718A1 (en) * | 2002-12-13 | 2004-07-09 | Warner-Lambert Company Llc | Gabapentin analogues for fibromyalgia and other related disorders |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
EP1572187A1 (en) * | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
WO2004084880A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
EP1608357A4 (en) * | 2003-03-31 | 2008-03-26 | Xenoport Inc | TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE |
US7662987B2 (en) * | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
KR20110097942A (ko) * | 2003-08-20 | 2011-08-31 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
EP1670451A4 (en) * | 2003-09-11 | 2009-10-21 | Xenoport Inc | TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS |
EP1675582A1 (en) * | 2003-09-12 | 2006-07-05 | Warner-Lambert Company LLC | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
BRPI0414481A (pt) * | 2003-09-17 | 2006-11-14 | Xenoport Inc | métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica |
MXPA06003396A (es) * | 2003-09-25 | 2006-06-08 | Warner Lambert Co | Profarmacos de aminoacidos con afinidad por la proteina a 2d. |
KR101096480B1 (ko) * | 2003-10-14 | 2011-12-20 | 제노포트 인코포레이티드 | 감마-아미노부티르산 유사체의 결정질 형태 |
US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
BRPI0517227B8 (pt) * | 2004-11-04 | 2021-05-25 | Xenoport Inc | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
US20060192353A1 (en) * | 2005-02-08 | 2006-08-31 | Schubert Peter J | Method of producing a rollover arming signal based on off-axis acceleration |
US20070049627A1 (en) * | 2005-08-23 | 2007-03-01 | Tran Pierre V | Treating vulvodynia using prodrugs of GABA analogs |
US20070049626A1 (en) * | 2005-08-26 | 2007-03-01 | Tran Pierre V | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
CN101616664A (zh) * | 2006-11-14 | 2009-12-30 | 克塞诺波特公司 | 加巴喷丁和普加巴林的前药用于治疗耳鸣的应用 |
US7868043B2 (en) * | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
EP2250148B1 (en) * | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
-
2007
- 2007-12-06 BR BRPI0720252-0A patent/BRPI0720252A2/pt not_active Application Discontinuation
- 2007-12-06 WO PCT/US2007/024944 patent/WO2008073257A1/en active Application Filing
- 2007-12-06 EA EA200970487A patent/EA200970487A1/ru unknown
- 2007-12-06 MX MX2009006080A patent/MX2009006080A/es not_active Application Discontinuation
- 2007-12-06 AU AU2007332904A patent/AU2007332904A1/en not_active Abandoned
- 2007-12-06 EP EP07867636A patent/EP2101752A1/en not_active Withdrawn
- 2007-12-06 CA CA002672044A patent/CA2672044A1/en not_active Abandoned
- 2007-12-06 CN CN200780051141A patent/CN101652133A/zh active Pending
- 2007-12-06 US US12/001,067 patent/US20080161393A1/en not_active Abandoned
- 2007-12-06 JP JP2009540287A patent/JP2010512314A/ja active Pending
- 2007-12-07 TW TW096146838A patent/TW200845959A/zh unknown
- 2007-12-10 AR ARP070105514A patent/AR064212A1/es unknown
- 2007-12-10 PE PE2007001760A patent/PE20081389A1/es not_active Application Discontinuation
-
2011
- 2011-10-27 US US13/283,469 patent/US20120041061A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2007332904A1 (en) | 2008-06-19 |
WO2008073257A1 (en) | 2008-06-19 |
US20120041061A1 (en) | 2012-02-16 |
EP2101752A1 (en) | 2009-09-23 |
EA200970487A1 (ru) | 2009-12-30 |
PE20081389A1 (es) | 2008-11-19 |
CN101652133A (zh) | 2010-02-17 |
TW200845959A (en) | 2008-12-01 |
MX2009006080A (es) | 2009-07-14 |
US20080161393A1 (en) | 2008-07-03 |
BRPI0720252A2 (pt) | 2014-01-07 |
JP2010512314A (ja) | 2010-04-22 |
CA2672044A1 (en) | 2008-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064212A1 (es) | Uso de profarmacos de analogos de gaba para tratar enfermedades | |
ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
MEP43308A (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
UA101328C2 (uk) | Похідні 6-триазолпіридинсульфанілбензотіазолу і -бензімідазолу, спосіб їх одержання (варіанти), застосування їх як лікарських засобів, фармацевтична композиціїя та застосування як інгібіторів met | |
NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
CL2008002330A1 (es) | Compuestos derivados de alcoholes de 1-fenil-2-piridinilalquilo, inhibidores de la fosfodiesterasa 4 (pde4); proceso de preparacion de dichos compuestos; composiciones farmaceuticas que los contienen; y su uso para preparar medicamentos utiles en la prevencion o tratamiento de asma, bronquitis cronica y epoc. | |
EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
BRPI0510365A (pt) | composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo | |
MX2009004289A (es) | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales. | |
ME01595B (me) | Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze | |
JP2011520815A5 (es) | ||
MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
PE20081493A1 (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso | |
EA200900178A1 (ru) | Конденсированные гетероциклические производные и их применение | |
CO5570670A2 (es) | Pulmonar obstructiva cronica | |
MX2010006209A (es) | Derivados de quinoxalinilo. | |
AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
BRPI0518615A2 (pt) | derivados de malonamida | |
MX2009003927A (es) | Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes. | |
RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
RS51190B (sr) | Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti | |
AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
TW200740760A (en) | Malonamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |